Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory
advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched …

Aim: The aim of this study is to determine the efficacy and safety of the combination therapy
of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration …

Purpose Anlotinib is widely used in the clinical treatment of non-small cell lung cancer
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …

Objectives Given the modest efficacy of docetaxel in advanced non-small cell lung cancer
(NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in …

Purpose Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown
favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell …

Background and Aim. Anlotinib, a novel tyrosine kinase inhibitor, has demonstrated
encouraging antitumor activity in bone and soft tissue sarcomas in several prospective …

Background The timely addition of anlotinib to the nab-paclitaxel/gemcitabine regimen may
further increase the treatment efficacy for pancreatic adenocarcinoma (PDAC), which has …

Background This multicenter phase 1b/2 trial aimed to explore the maximum tolerated dose
(MTD), activity, and safety of anlotinib plus chemotherapy in patients with T790M‐negative …

Background The physical tolerance in the advanced non-small cell lung cancer (NSCLC)
patient often deteriorates, with a limited effective rate of the third-line treatment. This study …